UAMS Myeloma Institute collaborates with Celgene Corporation and Dana-Farber Cancer Institute to Define Patient Segments for Targeted Therapy

UAMS Myeloma Institute collaborates with Celgene Corporation and Dana-Farber Cancer Institute to Define Patient Segments for Targeted Therapy